|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Human Genome Research Institute (NHGRI) |
|---|---|
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00001255 |
Purpose
This study will monitor the long-term effects of gene therapy in patients with severe combined immunodeficiency disease (SCID) due to a deficiency in an enzyme called adenosine deaminase (ADA). It will also follow the course of disease in children who are not receiving gene therapy, but may have received enzyme replacement therapy with the drug PEG-ADA.
ADA is essential for the growth and proper functioning of infection-fighting white blood cells called T and B lymphocytes. Patients who lack this enzyme are, therefore, immune deficient and vulnerable to frequent infections. Injections of PEG-ADA may increase the number of immune cells and reduce infections, but this enzyme replacement therapy is not a definitive cure. In addition, patients may become resistant or allergic to the drug. Gene therapy, in which a normal ADA gene is inserted into the patient's cells, attempts to correcting the underlying cause of disease.
Patients with SCID due to ADA deficiency may be eligible for this study. Patients may or may not have received enzyme replacement therapy or gene transfer therapy, or both. Participants will have follow-up visits at the National Institutes of Health in Bethesda, Maryland, at least once a year for a physical examination, blood tests, and possibly the following additional procedures to evaluate immune function:
| Condition | Intervention |
|---|---|
|
Severe Combined Immunodeficiency |
Drug: ADA PBSC Drug: ADA Umbilical Cord Blood Cells Drug: Transduced Lymphocytes |
| Study Type: | Observational |
| Official Title: | Treatment of Severe Combined Immunodeficiency Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency With Autologous Lymphocytes of CD34+ Cells Transduced With a Human ADA Gene: A Natural History Study |
| Estimated Enrollment: | 10 |
| Study Start Date: | September 1990 |
| Estimated Study Completion Date: | July 2002 |
The primary purpose of this study is to continue to provide clinical follow-up for ADA-deficient patients treated with gene therapy under the original protocol 90-HG-0195 (IND 3624) and its amendments (IND 4647 and IND 5056). The objectives are the long-term monitoring of the beneficial effects of gene therapy and continued surveillance of potential adverse effects associated with the gene transfer procedures.
No new subjects will be enrolled in this protocol.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
New patients will not be treated under protocol 90-HG-0195 as new and improved vectors and technologies have become available in the recent years.
New patients with ADA deficiency, however, may be enrolled in protocol 90-HG-0195 for clinical evaluation of their immune system and pre-treatment testing of transduction procedures.
Contacts and Locations
More Information
| Study ID Numbers: | 900195, 90-HG-0195 |
| Study First Received: | November 3, 1999 |
| Last Updated: | March 3, 2008 |
| ClinicalTrials.gov Identifier: | NCT00001255 History of Changes |
| Health Authority: | United States: Federal Government |
|
Retroviral Vector Gene Therapy PEG-ADA Severe Combined Immunodeficiency (SCID) Adenosine Deaminase Deficiency (ADA) |
|
Vasodilator Agents Metabolic Diseases Immune System Diseases Severe Combined Immunodeficiency DNA Repair-Deficiency Disorders Physiological Effects of Drugs Cardiovascular Agents Immunologic Deficiency Syndromes Pharmacologic Actions |
Sensory System Agents Therapeutic Uses Infant, Newborn, Diseases Anti-Arrhythmia Agents Analgesics Peripheral Nervous System Agents Adenosine Central Nervous System Agents |